Quick Answer
Calidi Biotherapeutics, Inc. reported Total Revenue of $45.0 thousand for fiscal year 2022.
Calidi Biotherapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | $45.0K | — |
| Revenue (ASC 606) | — | — | — | $45.0K | — |
| Net Income | -$19.91M +10.1% |
-$22.14M +24.2% |
-$29.22M -14.9% |
-$25.43M | — |
| Diluted EPS | -$5.95 +83.3% |
-$35.70 -106.0% |
-$17.33 -679.6% |
$2.99 | — |
| Total Assets | $8.86M -37.5% |
$14.18M +41.6% |
$10.02M +285.8% |
$2.60M -98.9% |
$231.77M |
| Cash and Equivalents | — | — | — | — | $1.06M |
| Stockholders Equity | $3.76M +145.0% |
$1.53M +118.6% |
-$8.23M +83.7% |
-$50.44M | $0.00 |
| R&D Expense | $9.74M +9.7% |
$8.88M -31.7% |
$13.01M +79.2% |
$7.26M | — |
| Operating Income | -$20.24M +7.1% |
-$21.78M +24.9% |
-$28.99M -25.4% |
-$23.13M | — |
| Shares Outstanding | 7.22M +317.2% |
1.73M -51.3% |
3.55M -58.6% |
8.58M -62.7% |
23.00M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$5.15M | -1.9% | +9.9% |
| Diluted EPS | September 30, 2025 | -$2.21 | +71.5% | -11.1% |
| Total Assets | September 30, 2025 | $14.03M | +110.7% | +50.0% |
| Cash and Equivalents | September 30, 2021 | $1.20M | — | — |
| Stockholders Equity | September 30, 2025 | $6.92M | +170.6% | +292.2% |
| R&D Expense | September 30, 2025 | $2.36M | +9.7% | -8.9% |
| Operating Income | September 30, 2025 | -$5.05M | +3.4% | +10.9% |
| Shares Outstanding | September 30, 2025 | 6.91M | -25.8% | +140.1% |
- Calidi Biotherapeutics, Inc. reported Total Revenue of $45.0 thousand for fiscal year 2022.
- Calidi Biotherapeutics, Inc. reported Revenue (ASC 606) of $45.0 thousand for fiscal year 2022.
- Calidi Biotherapeutics, Inc. reported Net Income of -$19.91 million for fiscal year 2025.
- Calidi Biotherapeutics, Inc. showed an increase of +10.1% in Net Income compared to the prior fiscal year.
- Calidi Biotherapeutics, Inc. reported Diluted EPS of $5.95 per share (loss) for fiscal year 2025.
- Calidi Biotherapeutics, Inc. showed an increase of +83.3% in Diluted EPS compared to the prior fiscal year.
- Calidi Biotherapeutics, Inc. reported Total Assets of $8.86 million for fiscal year 2025.
- Calidi Biotherapeutics, Inc. showed a decrease of -37.5% in Total Assets compared to the prior fiscal year.
- Calidi Biotherapeutics, Inc. reported Cash and Equivalents of $1.06 million for fiscal year 2021.
- Calidi Biotherapeutics, Inc. reported Stockholders Equity of $3.76 million for fiscal year 2025.
- Calidi Biotherapeutics, Inc. showed an increase of +145.0% in Stockholders Equity compared to the prior fiscal year.
- Calidi Biotherapeutics, Inc. reported R&D Expense of $9.74 million for fiscal year 2025.
- Calidi Biotherapeutics, Inc. showed an increase of +9.7% in R&D Expense compared to the prior fiscal year.
- Calidi Biotherapeutics, Inc. reported Operating Income of -$20.24 million for fiscal year 2025.
- Calidi Biotherapeutics, Inc. showed an increase of +7.1% in Operating Income compared to the prior fiscal year.
- Calidi Biotherapeutics, Inc. reported Shares Outstanding of 7.22 million shares for fiscal year 2025.
- Calidi Biotherapeutics, Inc. showed an increase of +317.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: